Accessibility Menu
Accuray logo

Accuray(NASDAQ) ARAY

Market Cap$31.77MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2007)-99%
5 Year-93%
1 Year-82%
1 Month-3%
$0.27
+0.30%
+0.00Today
Accuray last closing stock price
MetricPriceDate
Last closeUSD 0.272026-09-04
Accuray stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.59%USD 0.272026-08-28
1 month-2.73%USD 0.272026-08-05
3 month-21.97%USD 0.342026-06-05
Year to date-67.64%USD 0.822025-12-31
1 year-82.33%USD 1.512025-09-04
3 year-90.64%USD 2.852023-09-05
5 year-93.25%USD 3.952021-09-03
Since inception-99.07%USD 28.472007-02-08

Accuray Financials at a Glance

Market Cap

$31.77MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$401.95M

Net Income (TTM)

-$49.19M

EPS (TTM)

-$0.41

P/E Ratio

-0.65

Dividend

$0.00

Beta (Volatility)

1.59 (High)

Price

$0.27

Volume

291,811

Open

$0.27

Previous Close

$0.27

Daily Range

$0.25 - $0.27

52-Week Range

$0.22 - $2.10

Estimated Earnings Date

Nov 4, 2026

ARAY News

featured-earnings-leadership-highlights.png

Accuray Q4 Revenue Hits $128 Million

Motley Fool Markets TeamAug 14, 2025
Nurse tending patient in intensive care

Why Shares of Accuray Rose Thursday

James HalleyApr 27, 2023
xrayphoto

Why Shares of Accuray Jumped Thursday

James HalleyFeb 2, 2023
Accuray

Why Accuray Shares Are Soaring Today

Keith SpeightsJan 29, 2020
Accuray

Here's How Accuray Hit a Home Run With Its Q2 Earnings Update

Keith SpeightsJan 29, 2020
aray-radixact[1]

Accuray Reports Solid Earnings in its Second Fiscal Quarter

Brian Orelli, PhDJan 28, 2020
GettyImages-511732538

Better Buy: Intuitive Surgical vs. Accuray

Prosper Junior BakinyJan 9, 2020
Surgical robot system

Better Buy: Intuitive Surgical vs. Accuray

Keith SpeightsOct 31, 2019
Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Accuray

Accuray makes machines that help doctors treat cancer with targeted radiation. Its systems allow hospitals to deliver precise therapy to tumors, aiming to spare healthy tissue. These products are used by medical teams worldwide to improve patient care.

Products and Services

  • CyberKnife System: Robotic device for non-invasive tumor treatment; the company’s "products" revenue represented 51% of net revenue in the most recent period, including CyberKnife and TomoTherapy systems; used by hospitals and clinics.
  • TomoTherapy/Radixact System: Integrated platform for daily radiation therapy; serves cancer centers and hospitals.
  • iDMS Data Management: Software for planning and tracking treatments; supports clinicians in managing patient data.
  • Precision Treatment Planning: Software for customizing radiation plans; helps doctors tailor therapy to each patient.
  • Customer Support Services: Installation, training, and ongoing support; ensures equipment runs smoothly for healthcare providers.

Growth and Expansion

  • Formed joint venture with CNNC in China in 2019 to manufacture and sell local devices.
  • Launched Tomo C system in China in 2023, expanding product reach in Asia.
  • Secured regulatory approvals for new systems in China in January 2025, including Radixact SynC and CyberKnife S7.
  • Increased investment in manufacturing and software development since 2024 to support product innovation.

What Makes Accuray Stand Out

Accuray derives most of its revenue from international operations, which are reported across five geographic regions. Its systems focus on precision, aiming to reduce side effects for patients. The company’s joint venture in China supports local manufacturing and regulatory access.

Five Things You Need to Know

  • Revenue was $102 million in QQ2 2026, down 12% from QQ2 2025.
  • Gross profit was $24 million in QQ2 2026, down 42.5% year-over-year.
  • International sales made up 82% of revenue in the quarter ending March 2025.
  • Order backlog was $452.4 million as of March 31, 2025, down 10% year-over-year.
  • Cash and equivalents were $77.8 million as of March 31, 2025.

Bottom Line

Accuray has evolved through global expansion, product innovation, and strategic partnerships. The company faces industry challenges but remains focused on precision cancer therapy solutions.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

809

CEO

Stephen R. la Neve, MBA

Website

www.accuray.com

Headquarters

Madison, WI 53717-1954, US

ARAY Financials

Key Financial Metrics (TTM)

Gross Margin

27.73%

Operating Margin

-6.58%

Net Income Margin

-12.24%

Return on Equity

-99.04%

Return on Capital

-11.72%

Return on Assets

-11.09%

Earnings Yield

-1.54%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$31.77MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

119.44M

Volume

291.81K

Avg. Volume

1.41M

Financials (TTM)

Gross Profit

$111.45M

Operating Income

-$26.44M

EBITDA

-$14.34M

Operating Cash Flow

-$6.98M

Capital Expenditure

-$6.90M

Free Cash Flow

-$13.88M

Cash & ST Invst.

$40.62M

Total Debt

$183.87M

Accuray Performance Analysis

Accuray annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30USD 447,605,0004.1%
20242024-06-30USD 446,551,000-0.2%
20252025-06-30USD 458,505,0002.7%
20262026-06-30USD 401,947,000-12.3%
Accuray sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-09-30-26.3%
Q22025-12-318.8%
Q32026-03-312.5%
Q42026-06-30-3.7%
Accuray annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30USD -0.1068.3%
20242024-06-30USD -0.1661.8%
20252025-06-30USD -0.02-90.2%
20262026-06-30USD -0.402487.7%
Accuray sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-09-30-1847.6%
Q22025-12-3138.9%
Q32026-03-3118.2%
Q42026-06-3082.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

$100.92M

-20.9%

Gross Profit

$35.54M

-8.8%

Gross Margin

35.22%

N/A

Market Cap

$31.77MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$39.27K

N/A

Employees

809

N/A

Net Income

-$1.94M

-272.8%

EBITDA

$71.00K

-99.1%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

$40.62M

-29.2%

Total Debt

$183.87M

+4.3%

Accounts Receivable

$67.41M

-31.1%

Inventory

$147.08M

+4.3%

Long Term Debt

$174.14M

+11.4%

Short Term Debt

$9.74M

-51.6%

Return on Assets

-11.09%

N/A

Return on Invested Capital

-10.48%

N/A

Free Cash Flow

$1.97M

+115.0%

Operating Cash Flow

$2.43M

+125.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RANIRani Therapeutics Holdings, Inc.
$0.87+1.54%
RPIDRapid Micro Biosystems, Inc.
$1.31-5.07%
OWLTOwlet, Inc.
$4.98-0.99%
LNSRLENSAR Inc
$8.58+4.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.15-0.12%
NVDANvidia
$230.36+0.01%
PATHUiPath
$15.19-0.17%
INTCIntel
$95.80+0.05%

Questions About ARAY

What is the current price of Accuray?

Accuray is trading at $0.27 per share.

What is the 52-week range for Accuray?

Over the past 52 weeks, Accuray has traded between $0.22 and $2.10.

How much debt does Accuray have?

As of the most recent reporting period, Accuray reported total debt of $187.71M.

How much cash does Accuray have on hand?

Accuray reported $41.23M in cash and cash equivalents in its most recent financial results.

What is Accuray’s dividend yield?

Accuray does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services